AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment
Betsy Goodfellow | November 6, 2023 | News story | Research and Development | AstraZeneca, CKD, Nephrology, kidney disease, proteinuria
AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the treatment of patients with chronic kidney disease (CKD) and proteinuria.
This combination demonstrated statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ration (UACR), used to assess albuminuria, at 12 weeks when compared to treatment with dapagliflozin alone.
These results were presented at the American Society of Nephrology (ASN) Kidney Week 2023 as well as having been published in The Lancet.
Sharon Barr, executive vice president of BioPharmaceuticals Research and Development at AstraZeneca, commented: “Despite current treatment options, residual proteinuria persists in a sizeable portion of patients and is associated with a high risk of kidney failure. The evidence published today supports advancement of zibotentan/dapagliflozin into a phase 3 clinical trial to further assess its potential as a first-in-class treatment for residual proteinuria in CKD.”
The company plans to progress the drug combination to a phase 3 trial; it is intended that this will begin in the final quarter of 2023.
Betsy Goodfellow
Related Content
AstraZeneca to build $1.5bn ADC facility in Singapore
AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, …
AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug
AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 …
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …